Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:BIIB 25 August 2025 - 1 April 2026

Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Biogen agreed to buy Apellis Pharmaceuticals for $5.6 billion, offering $41 per share in cash plus sales-based rights tied to the eye drug Syfovre. Apellis shares traded at $40.23 after the announcement. The deal includes a contingent value right worth up to $4 if Syfovre hits certain sales milestones. Apellis’ board and key shareholders, holding 14%, backed the offer, which is expected to close in the second quarter.
1 April 2026
···
Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics shares dropped 1.2% to $35.80 in early premarket trading Tuesday, after a 5.7% gain the previous session. Wolfe Research began coverage with an “Outperform” rating and a $40 price target. Investors are watching for updates on the company’s Phase 3 Dravet syndrome trial with Biogen. About 21.6% of Stoke’s float is sold short, according to MarketBeat.
24 February 2026
···
Biogen (BIIB) Stock News Today (Dec. 22, 2025): QALSODY Data, Nasdaq-100 Exit, and Analyst Forecasts

Biogen (BIIB) Stock News Today (Dec. 22, 2025): QALSODY Data, Nasdaq-100 Exit, and Analyst Forecasts

Biogen shares traded near $175 on Dec. 22 as the company announced JAMA Neurology published final long-term results from its Phase 3 VALOR study of QALSODY for SOD1-ALS. The stock was removed from the Nasdaq-100 index today, following a surge in volume last Friday. Analyst ratings remain mixed, with price targets ranging from the low-$140s to above $200.
22 December 2025
·
Biogen Stock Forecast for the Week Ahead (Dec. 22–26, 2025): BIIB Near 52-Week High as Leqembi Momentum Meets an Analyst Split

Biogen Stock Forecast for the Week Ahead (Dec. 22–26, 2025): BIIB Near 52-Week High as Leqembi Momentum Meets an Analyst Split

Biogen shares closed at $174.80 on Dec. 19, up 2.88% with trading volume spiking to 15 million shares, well above the 50-day average. The stock remains about 5% below its 52-week high of $185.17. Recent filings show new institutional positions from Wedge Capital Management and Fluent Financial. Leqembi was added to China’s Commercial Insurance Innovative Drug List, effective Jan. 1, 2026.
21 December 2025
··
Biogen Stock (BIIB) After-Hours on Dec. 19, 2025: Why Shares Jumped, Where They Closed After the Bell, and What to Watch Before the Next Market Open

Biogen Stock (BIIB) After-Hours on Dec. 19, 2025: Why Shares Jumped, Where They Closed After the Bell, and What to Watch Before the Next Market Open

Biogen shares closed up 2.88% at $174.80 Friday, with trading volume surging to about 15 million shares, far above the 50-day average. The move followed bullish analyst commentary from RBC Capital, which reiterated an “Outperform” rating and a $210 price target. After-hours, BIIB edged higher to $176.23. Renewed focus on Alzheimer’s treatments and pipeline prospects drove activity.
20 December 2025
·
BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

Biogen shares hit a 52-week high Monday, closing at $177.42, up 1.2%, after Novo Nordisk’s Alzheimer’s drug failed in late-stage trials. The stock traded as high as $185.17 intraday on volume of about 2.07 million shares. Investors also reacted to Biogen’s new immunology partnership with Dayra Therapeutics. Novo shares fell sharply on the trial news.
24 November 2025
··
Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen shares fell about 2.6% after hours Oct. 30 following Q3 results that beat estimates, with revenue at $2.53 billion and adjusted EPS of $4.81. The company cut 2025 non-GAAP EPS guidance to $14.50–$15.00, citing a $1.25 per-share R&D charge. Leqembi sales reached $121 million, up 80% year-over-year. Biogen licensed Vanqua Bio’s inflammation drug for up to $1.06 billion.
30 October 2025
··
Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

U.S. stocks closed at record highs despite a partial government shutdown, with the S&P 500 up 0.34% to 6,711.20 and the Dow rising 0.09% to 46,441.10. Health-care shares jumped after Pfizer and the White House struck a drug price deal, sending Biogen up 10.9%. The ADP report showed private-sector jobs fell by 32,000 in September, but investors bet on Fed rate cuts.
1 October 2025
·····
Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

Researchers used AI to design the first viruses from scratch, creating bacteriophages that killed drug-resistant bacteria. Scientists solved why smoking affects ulcerative colitis and Crohn’s disease differently, linking it to mouth bacteria. New Alzheimer’s drugs modestly slowed disease in early stages. Wildfire smoke could kill 70,000 Americans annually by 2050, Stanford researchers warned.
20 September 2025
·····
FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

The FDA approved Ionis’ Dawnzera as the first RNA-targeted preventive treatment for hereditary angioedema, after trials showed an 81% drop in attack rates. Regulators rejected PTC Therapeutics’ vatiquinone for Friedreich’s ataxia, citing insufficient efficacy data and requesting another trial. Jazz Pharmaceuticals secured approval for dordaviprone to treat rare pediatric brain tumors.
25 August 2025
······

Stock Market Today

  • JPMorgan Upgrades Capital One Despite 2026 Stock Drop, Sees 10.6% Upside
    April 9, 2026, 9:31 AM EDT. JPMorgan upgraded Capital One Financial to overweight from neutral amid a 20% drop in its 2026 stock price. Analyst Richard Shane cut the price target to $213 but still sees a 10.6% gain from Wednesday's close. The downgrade in price target reflects cautious views on consumer risks, including high energy costs and inflation. Shane cited the completion of Capital One's Discover Financial Services merger as a positive thematic factor. JPMorgan believes Capital One's strong reserves can shield it from worsening macroeconomic conditions, limiting further downside unless new risks materialize. The upgrade signals a buy-the-dip approach despite ongoing economic uncertainty.

Latest article

American Airlines Faces FAA Fine Over Drug-Testing Lapses in New Test for 2026 Turnaround

American Airlines Faces FAA Fine Over Drug-Testing Lapses in New Test for 2026 Turnaround

9 April 2026
The FAA proposed a $255,000 civil penalty against American Airlines, alleging the carrier allowed 12 flight attendants who tested positive for drugs or alcohol to return to safety-sensitive duties before completing required follow-up tests. The alleged violations occurred from May 2019 to December 2023. American has 30 days to respond. The airline said it is reviewing the notice.
Hologic goes private: Blackstone, TPG close buyout and name José Almeida CEO

Hologic goes private: Blackstone, TPG close buyout and name José Almeida CEO

9 April 2026
Blackstone and TPG closed their $17.3 billion acquisition of Hologic on April 7, with José Almeida replacing Steve MacMillan as CEO. Hologic shares were suspended before trading that day and will be removed from the S&P 500 before Thursday’s open. Former shareholders will receive $76 per share in cash plus a contingent value right worth up to $3 more if revenue targets are met.
When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

9 April 2026
Brent crude rebounded 3% Thursday despite a U.S.-Iran ceasefire, with the Strait of Hormuz still nearly shut and only one oil-products tanker passing in 24 hours. U.S. gasoline averaged $4.166 a gallon on April 9, and AAA said prices could drop slowly. North Sea Forties crude hit a record $146.43 a barrel. The U.S. EIA expects Hormuz flows may take months to recover.
CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

9 April 2026
CoreWeave said Meta Platforms committed about $21 billion for AI cloud capacity through December 2032. Shares rose 4.3% to $88.90 in premarket trading after the announcement. The deal follows an $8.5 billion loan facility and a $1.25 billion senior notes offering. CoreWeave reported $5.13 billion in 2025 revenue and ended December with a $66.8 billion backlog.
Go toTop